Chloro, bromo, and mixed bromochloro haloacetates (HAs) are by-products of drinking water disinfection and are hepatocarcinogenic in rodents. We compared the toxicokinetics of a series of di-HAs, dichloro (DCA), bromochloro (BCA), dibromo (DBA) and tri-HAs: trichloro (TCA), bromodichloro (BDCA), chlorodibromo (CDBA), and tribromo (TBA) after iv and oral dosing (500 m/kg) in male F344 rats. The blood concentrations of the HAs after iv injection declined in a bi-exponential manner with a short but pronounced distributive phase. The structural features that had the greatest influence on the disposition of HAs were substitution of a halogen for a hydrogen and the degree of bromine substitution. All di-HAs had blood elimination half-lives of less than 4 h (DCA > DBA, BCA) compared to the tri-HAs, which had half-lives that varied from 0.6 to 8.0 h (TCA > BDCA > CDBA > TBA). The urinary excretion of all di-HAs was low and accounted for less than 3% of the dose in contrast to the tri-HAs, where urinary excretion accounted for at least 30% of the dose. Toxicokinetic analysis indicated the steady-state apparent volume of distribution varied between 301 and 881 ml/kg among the HAs, but the variation was not statistically significant (P > 0.17). The blood concentration-time profiles for all di-HAs after oral dosing was complex and exhibited multiple peaks. This did not appear to be due to enterohepatic recirculation, as bile duct cannulated animals also displayed similar profiles. In contrast, the profiles for the tri-HAs did not exhibit multiple peaking after oral dosing and could be described using a one-compartment pharmacokinetic model. The oral bioavailability of the HAs varied between 30% (DBA) and 116% (TCA), depending on the number of halogen substituents and the degree of bromine substitution. In general, three patterns of elimination for the HAs can be broadly described: low metabolism with moderate renal clearance (TCA), high metabolism and renal clearance (BDCA, CDBA, TBA), and high metabolism, low renal clearance (DCA, BCA, DBA).
The disinfection of drinking water can produce a variety of halogenated by-products (Krasner et al., 1989; Singer and Chang, 1989; Singer, 1993) . Haloacetates (HAs) are an important class of by-products dominated by the chlorine and bromine substituted forms. Concentrations in excess of 100 g/L of chlorinated, brominated and mixed chlorobromo HAs can be formed in drinking water depending on the disinfection method and chemical characteristics of the source water (Pourmoghaddas et al., 1993; Williams et al., 1997) . All possible combinations of chlorine and bromine substitutions in HAs are found in drinking water, although the di-and tri-HAs tend to predominate (Pourmoghaddas et al., 1993) . These more commonly identified HAs are shown in Fig. 1 .
Toxicological studies of HAs have concentrated on the fully chlorinated forms, where both dichloroacetate (DCA) and trichloroacetate (TCA) are well-established rodent carcinogens (Herren-Freund et al., 1987; Bull et al., 1990; DeAngelo et al., 1991 DeAngelo et al., , 1996 Daniel et al., 1992; Pereira, 1996) . More recently, several of the brominated HAs have been shown to be hepatocarcinogenic in the B6C3F1 mouse (Stauber and Bull, 1995) . This is consistent with findings that bromine substitution increases both the mutagenicity and the reproductive and developmental toxicity of HAs Linder et al., 1994 Linder et al., , 1997 Giller et al., 1997) .
Previous toxicokinetic studies of HAs have focused on TCA, DCA, and bromodichloroacetate (BDCA). A common finding with these HAs is the rapid and complete absorption from the gastrointestinal tract after oral dosing, with little fecal elimination of the parent HA or metabolites (Larson and Bull, 1992; Lin et al., 1993; Xu et al., 1995; Gonzalez-Leon et al., 1997) . Once absorbed, the elimination of TCA and DCA differs substantially, with TCA having a blood or plasma elimination half-life that is up to 20 times longer than that of DCA . The more rapid elimination of DCA is primarily due to greater metabolism, with up to 58% of an administered dose being converted to CO 2 within 24 h in F344 rats (Gonzalez-Leon et al., 1997) . A comparison of TCA, BDCA, and DCA metabolism in mice revealed that CO 2 excretion as a fraction of administered dose followed the order DCA Ͼ BDCA Ͼ TCA (Xu et al., 1995) . These results provide an indication of the complex differences that may exist in the toxicokinetics and metabolism of di-and tri-HAs.
The exposure to HAs found in drinking water invariably occurs as a mixture and rational approaches for exposure determination of HAs need to be developed. Progress in this area is currently limited by a paucity of information regarding the brominated HAs. The present study is an initial attempt to overcome this limitation by characterizing the comparative toxicokinetics of di-and tri-HAs in F344 rats. We administered 500 M oral and iv doses of the HAs shown in Fig. 1 and determined the blood concentration-time profiles for each HA. These data sets were subjected to toxicokinetic analysis to provide quantitative estimates of parameters describing the absorption, distribution, and excretion of the HAs. Additionally, octanol-buffer (pH 4.0, 7.4) partitioning, blood-plasma partitioning, and plasma protein binding were measured.
METHODS
Chemicals. DCA (purity Ͼ99%) and DBA (purity Ͼ98%) were purchased from Fluka Chemical Corp. (Milwaukee, WI) . BDCA, CDBA, TBA (all ϳ99% pure), and BCA (purity 98.2%) were purchased from Supelco Inc. (Bellefonte, PA). Reagent grade methyl-tert-butyl ether was purchased from Fisher Scientific (Pittsburgh, PA). Diazomethane was prepared from N-methyl-N-nitrosoguanidine following Aldrich Technical Information Bulletin Number AL-121 (Aldrich Technical Services, Milwaukee, WI). All other chemicals were of reagent grade or better and were obtained from standard sources.
The chemical purities of selected HAs were further verified by sequential HPLC fractionation and GC-ECD. Aliquots from stock solutions (50 M) of BDCA and TBA were injected onto an isocratic, ion-pairing HPLC system consisting of a 4-m 3.9 ϫ 150 cm C 18 column (Nova-Pak, Waters Co., Milford, MA) and a mobile phase of 80% water and 20% methanol (v/v) containing 15 mM tetramethylammonium hydrogen sulfate (Sigma-Aldrich, St. Louis, MO) as an ion-pairing agent. The mobile phase flow rate was 0.75 ml/min, and column effluent was monitored with a UV detector set at 220 nm. Under these chromatographic conditions, the retention times (min) were 2.0 (DCA), 3.7 (DBA), 4.0 (BDCA), 5.5 (TBA). Fractions corresponding to each HA were then collected and subsequently analyzed by GC-ECD as described under Analytical Methods. Chemical purities calculated by these methods were found to be identical to those reported by the vendors supplying the HAs.
Animals and treatment.
Male F344 rats, 8 -10 weeks in age (mean body weight Ϯ SD: 166 Ϯ 19 g; n ϭ 59) and fitted with a jugular vein cannula, were obtained from Charles River Laboratories (Raleigh, NC). Additional male F344 rats (mean body weight Ϯ SD: 176 Ϯ 13 g; n ϭ 3) fitted with both a jugular vein and bile duct cannula were obtained from Hilltop Laboratories (Scottsdale, PA). All animals were housed at 22°C and 40 -60% humidity under a 12-h light-dark cycle. Animals were allowed a minimum of 48 h recovery from transport and then were fasted overnight prior to administration of a HA. Animals were administered a 500 m/kg dose of an HA by iv injection or oral gavage and housed in polycarbonate metabolism cages. All dosing solutions were prepared in 0.9% (w/v) NaCl (administered volume was 1 ml/kg) and pH adjusted to 7.0 prior to administration. A typical blood sampling schedule after iv or gavage dosing was 0, 5, 10, 20, 30, 45, 60, 90, 120, and 180 min and variously thereafter, up to 24 or 48 h (TCA only) . At each sampling time, approximately 0.05 ml of blood was removed and mixed with 0.2 ml of ice-cold 0.1 M sodium acetate buffer (pH 5.2) and frozen at Ϫ20°C until later analysis. Actual blood sample volumes were determined gravimetrically using tared vials and assuming blood density was 1.05. Urine and feces were collected after 24 and 48 h (TCA only) from iv dosed animals and stored at Ϫ20°C until later analysis.
Additional experiments were performed to measure the biliary excretion of DCA. For these experiments, DCA was orally administered and blood samples were removed as described previously. Bile was continuously collected at 30-min intervals for 6 h, and the concentration at the midpoint of each collection interval was reported.
Determination of plasma protein binding and blood-to-plasma and octanol-to-buffer partitioning. Plasma protein binding was measured using the Centrifree micropartition system (mol wt cutoff 10,000 -12,000; Amicon Inc., Beverly, MA). Rats were administered HA (500 m/kg) via a jugular vein cannula, and blood samples (0.25 ml) were removed and divided into aliquots for determination of whole blood and plasma concentrations of the HA. Plasma was obtained after centrifugation (3000g for 5 min) of the blood sample. Blood samples were removed at 0.25, 1, and 2 h. A 0.05-ml aliquot was reserved to determine the total plasma concentration, and the remainder immediately was loaded into Centrifree units and centrifuged for 25 min at 1500g at 37°C. The initial 0.05 ml of ultrafiltrate collected was discarded. The ultrafiltrate and the plasma aliquot were analyzed for HAs as described below. Calculation of the unbound fraction of HA was made using the equation
The binding of all HAs to the ultrafiltration membrane was determined to be less than 10%. Calculation of the blood/plasma ratio was made from the measured HA concentrations in aliquots of whole blood and plasma, adjusted to a volume of 1 ml. The distribution of HAs between n-octanol and buffered solutions was performed using methods described by Stopher and McClean (1990) and Walker et al. (1996) except 100 g of HA was added to 2 ml of buffer and mixed overnight with 2 ml of octanol. Distribution coefficients were measured at pH 7.4 (D 7.4 ) using a 0.1 M sodium phosphate buffer and at pH 4.0 (D 4.0 ) using a 0.1 M sodium citrate buffer.
Analytical methods. All samples were analyzed for the HAs based on methods previously described for the chlorinated HAs, DCA, and TCA (Gonzalez-Leon et al., 1997; Merdink et al., 1998) with subsequent modifications designed to reduce degradation during analytical work-up as described in Merdink et al. (1998) . Because HAs are nonvolatile and highly water soluble, all samples must be extracted under acidic conditions and derivatized prior to GC analysis. Samples (0.05 ml blood, plasma, urine, ultrafiltrate, buffer, or octanol) were mixed with 0.025 ml of the internal standard: DBA for samples containing DCA, BCA, and BDCA; TCA for samples containing TBA and DBA. Next, an additional 0.3 ml of 0.1 M acetate buffer (pH 5.2) was added and mixed in a 1.5-ml polypropylene microcentrifuge vial. After mixing, the samples were acidified by adding 0.025 ml of 50% sulfuric acid and extracted into 0.9 ml of methyl tert-butyl ether. The free acids were converted to their methyl esters by the addition of 0.025 ml of ethereal diazomethane. Samples were then analyzed by GC-ECD (Hewlett-Packard 5890, Avondale, PA). The GC was operated in split mode with a 3:1 split ratio. The analytes were separated on a DB-WAX column (0.5 mm i.d., 0.3 m, 30 m, J&W Scientific, Folsom, CA); the chromatographic conditions were as follows: injection port temperature, 170°C, detector temperature, 300°C, initial temperature, 90°C, initial time, 7 min, rate A, 12°C/min, temp A, 175°, rate B, 30°C/min, final temperature, 210°C.
Although GC-ECD analysis provides high sensitivity for the parent HA, some degradation of the tri-HAs may occur during the acid extraction and GC analysis steps. Prior studies using TCA have described the influence of sample handling (Ketcha et al., 1996) and GC operating conditions , which can lead to dechlorination and subsequent formation of DCA. During method development for the present study, it became apparent this problem is even more pronounced with the brominated tri-HAs (BDCA, CDBA, and TBA), which will readily lose a bromine atom forming the more stable, di-HA. Consequently, small quantities of DCA, BCA, or DBA were always observed in analyses of BDCA, CDBA, or TBA standard solutions prepared from blank tissues and fluids. Therefore, caution must be used in interpreting the significance of any di-HA present in experimental samples that also contain substantial quantities of a tri-HA, because the source may be due to an artifact of the analytical method. In this study, background levels of tri-HA degradation within each sample matrix were routinely determined at multiple concentrations for each tri-HA. The indicator used to quantify any degradation was the percentage peak area ratio of di-HA present in tri-HA standards: di-HA peak area/(di-HA peak area ϩ tri-HA peak area) ϫ 100. A summary of typical levels of degradation observed in standard solutions prepared from saline, urine, and blood is shown in Table 1 . Also shown in Table 1 is the calculated method detection limit (MDL) for each HA determined from 0.05 ml of whole blood fortified with a quantity of a HA that produced a peak area approximately five times above the background noise (Glaser et al., 1981) . The MDL was calculated by multiplying the standard deviation of the peak areas from replicate standards (n ϭ 7) by Student's t value for n Ϫ 1 df for a 99% confidence interval.
Toxicokinetic analysis.
The individual blood concentration-time profiles measured after iv injection of each HA were analyzed by noncompartmental methods to obtain estimates of total body clearance (Cl b ), apparent volume of distribution at steady-state (V ss ), and the mean residence time (MRT) using standard equations (Gibaldi and Perrier, 1982) . The AUC 03ϱ was calculated by the linear trapezoidal method with the terminal portion of the curve extrapolated to infinity by C b,t /␤, where C b,t is the concentration at the last observation and ␤ is the slope of the terminal phase determined by linear regression. For the di-HAs, both the complete and a truncated portion of the concentrationtime profile were used to determine ␤ and AUC 03ϱ . When truncating a concentration-time profile, the analysis was restricted to data collected until 4 h after injection. The elimination half-life (t 1 2␤ ) was calculated as ␤/0.693. Renal clearance was calculated as Cl r ϭ X u0324 /AUC 0324 with X u0324 being the total amount of HA recovered in the urine after 24 h. The renal clearance of TCA was calculated from the 48-h urinary excretion data. The AUC values used to calculate renal clearance were converted to plasma AUC values by dividing the blood AUCs by the blood/plasma partition coefficient, which was determined separately for each HA.
Both noncompartmental and compartmental modeling methods were used to analyze the concentration-time profiles collected after oral dosing. Noncompartmental methods were used to determine the AUC 03ϱ , MRT, and t 1 2␤ using the complete concentration-time profiles. The profiles for the tri-HAs were also fitted to a one-compartment clearance-volume pharmacokinetic model using Eq. (2) and WinNonlin (Pharsight Corp., Cary, NC), a nonlinear least squares regression program. This approach was used to obtain estimates of absorption rate, peak blood concentration (C max ), and the time of occurrence (T max ).
In this equation, K a is the first-order absorption rate constant, K e is the first-order elimination rate constant, F is bioavailability, D is dose, and V is the volume of distribution. Preliminary analysis indicated that this model provided a better fit of the data than a two-compartment model. Initial estimates were obtained using the method of residuals (Gibaldi and Perrier, 1982) . For TBA, a modified form of Eq. (2) was used because preliminary analysis indicated the absorption and elimination rates were equal (i.e., K a ϭ K e ):
For this situation, initial estimates of K were obtained from the slope of a plot of ln (C b,t ) versus time as described by Hoke and Ravis (1992) . The model predicted K a , and C max and T max were calculated by the WinNonlin program using standard equations (Gibaldi and Perrier, 1982) . The oral bioavailability was calculated from the ratio of the averaged values for the AUC 03ϱ for the oral and iv doses. The mean absorption time (MAT) was calculated as the difference between the MRT oral and MRT iv . The concentration-time profiles for the di-HAs were not subjected to compartmental analysis (see Results), which prevented determination of the K a for these compounds.
Statistics. Significant differences between pharmacokinetic parameter estimates from the different treatment groups were assessed by one-way analysis of variance (ANOVA: p Ͻ 0.05). Note. Values shown are the percentages of mono-dehalogenated product formed in standards fortified with a HA at concentrations between 25 and 100 M. Also included in the table is the method detection limit (MDL) for HAs in blood.
a Percentage degradation was calculated from mono-dehalogenated peak area/(dehalogenated ϩ parent HA peak areas) ϫ 100.
b The observed degradation products were TCA 3 DCA; BDCA 3 DCA; CDBA 3 BCA; TBA 3 DBA. No dechlorination of mixed chlorobromo-HAs was observed.
c MDL was calculated as SD ϫ 3.143, where SD is 1 standard deviation of the peak areas obtained from replicate blood standards (n ϭ 7) fortified with a HA at concentrations producing peak areas approximately five times the background noise. The value of 3.143 represents the Student t value for 99% confidence with 6 df.
RESULTS
Intravenous administration. After iv injection, blood concentrations of most HAs rapidly declined and were below the assay MDL by 12 h. The notable exception was TCA, where measurable blood concentrations were still observed after 24 h. The averaged (mean Ϯ SD) blood concentration-time profiles for tri-and di-HAs are shown in Figs. 2 and 3. To facilitate comparison of the profiles between the different HAs, all values are expressed on a molar basis. Visual inspection of the curves indicated that the profiles appeared to decline in a bi-exponential manner, with a short distributive phase followed by a log-linear decline. For the di-HAs, the appearance of the log-linear phase seemed to be slightly delayed compared to the tri-HAs and occasional "tailing" or flattening of the profile at low blood concentrations (Ͻ10 M) could be observed in some animals. This phenomenon is particularly pronounced for BCA (Fig. 3) . After iv injection of BDCA, CDBA, or TBA, blood levels of the corresponding mono debrominated product (DCA, BCA, DBA) did not exceed the quantities observed in blood standards as shown in Table 1 .
To provide consistency in the data analysis, all profiles obtained from iv dosing experiments were analyzed using noncompartmental methods. This included reanalyzing data previously published for DCA (Gonzalez-Leon et al., 1997) , which used a compartmental modeling approach. There was some uncertainty in the start of the log-linear portion of the profiles for the di-HAs, which in some animals, did not appear until after 4 h. Therefore, toxicokinetic parameters for the di-HAs were calculated using both the complete profile and a truncated version, which only used data collected until 4 h. The summary of these toxicokinetic analyses is presented in Table  2 . The most apparent differences in the toxicokinetics of the HAs were in the AUC 03ϱ and renal excretion. All tri-HAs were extensively eliminated into the urine and at least 30% of the dose could be recovered as parent compound after 24 h ( Table  2 ). The renal clearance (Cl r ) for tri-HAs accounted for 23-46% of the total body clearance (Cl b ). In contrast, only small quantities of the di-HAs (Ͻ3% of the dose) were recovered in the urine and the Cl r accounted for a minor fraction of the Cl b . In addition, only negligible quantities of parent HA (Ͻ0.1% of dose) were recovered in the feces (data not shown). Among the tri-HAs, increased bromine substitution decreased the AUC 03ϱ and increased both the Cl b and Cl r . Bromine substitution in di-HAs increased the Cl b 2-to 4-fold compared to DCA. There was remarkable similarity in the steady-state apparent volume of distribution among all HAs that was not statistically different ( p Ͼ 0.176). The combined effects of a similar distributive volume and increasing clearance with bromine substitution are reflected in the elimination half-lives, which progressively decrease with bromine substitution among both HA classes ( Table 2) . Comparison of the parameters calculated for the di-HAs indicated that truncating the concentration-time profiles did not significantly affect calculation of the AUC 03ϱ and hence, estimation of V ss and Cl b . However, estimation of the elimination half-life could be markedly altered, increasing more than fivefold for BCA when calculated from the complete profile (Table 2) .
Oral administration. All HAs rapidly appeared in the blood after oral dosing and maximum blood concentrations were normally reached around 1 h after dosing (Figs. 4A-D and 5A-D). The di-HAs displayed complex blood concentration-time profiles, with secondary maximum concentrations occurring 2-8 h after dosing (Figs. 5A-C) . The multiple peaks for DCA did not appear to be due to enterohepatic recycling, as bile concentrations of DCA mirrored blood concentrations and were within 1-3 times the blood concentration values (Fig.  5D ). During these experiments, bile flow averaged 3.60 Ϯ 0.51 ml/h/kg and a total of 1.08 Ϯ 0.26% (mean Ϯ SD) of the DCA dose was excreted into bile over the 6-h collection period.
The summary of the compartmental and noncompartmental analyses of the concentration-time profiles after oral dosing is shown in Table 3 . The primary difference in parameter estimates was in the AUC 03ϱ , which in general, was higher for the tri-HAs. Among the tri-HAs, bromine substitution caused a decrease in the AUC 03ϱ (Table 3) . Maximum blood levels of most tri-HAs were approximately two times greater than the di-HAs. The absorption rate of the tri-HAs appears to be similar, and no statistically significant differences in K a were observed ( p Ͼ 0.08). The mean absorption time was similar for bromine substituted HAs, but was three to four times longer for TCA and DCA (Table 3 ). The only HAs that appear to have a significantly reduced oral bioavailability (e.g., Ͻ80%) were DBA, BCA, and TBA, whose values ranged from 30% to 62%.
Plasma binding, blood/plasma partitioning, and HA distribution coefficients.
The binding of HAs to rat plasma showed considerable variation, with the unbound fraction ( f u ) ranging from 0.18 to 0.94 (Table 4 ). All of the di-HAs exhibited low binding to plasma and the f u was between 0.89 and 0.94. In contrast, all tri-HAs were at least 50% bound to plasma, with TBA being the most highly bound of this HA class, with a f u of 0.18. The concentration ratio of the di-HAs between blood and plasma was very close to unity (Table 4) , which would indicate equal distribution between erythrocytes and plasma. The concentration ratio for the tri-HAs was lower, varying between 0.66 and 0.82 (Table 4) .
The experimentally determined distribution coefficients for the HAs is shown in Table 5 . Also included for comparison in Table 5 , are values for pK a and the calculated octanol-water partition coefficients (C log P) of HAs. These values were obtained from the literature or provided by A. Richards (personal communication). From inspection of Table 5 , it is clear that the lipophilicity of all HAs is low (e.g., log D values range from Ϫ1.39 to Ϫ1.92) at pH values near that of blood (pH 7.4) or urine and stomach/gastrointestinal fluids (pH 4.0) for rats. This is in contrast to predicted values of lipophilicity based on the fully nonionized form of the HA (C log P).
DISCUSSION
The results of this study indicate the primary difference in the toxicokinetics of HAs is in elimination. Both the extent of Note. Values are means Ϯ SD. Parameter estimates were calculated from the individual blood-concentration time profiles (n ϭ 4-6) using noncompartmental methods and were based on data collected until the last detectable value or until 12 h (48 h for TCA). Also included for the di-HAs are parameter estimates based on data obtained through 4 h (0-4).
a Values are not significantly different ( p Ͼ 0.176). b Renal clearance (Cl r ) was calculated from the amount of parent haloacid excreted in the urine (X u nm) divided by the AUC of the blood concentration time profiles adjusted for the blood/plasma concentration ratio of each HA.
c Nonrenal clearance (Cl nr ) was calculated from the difference between the total body (Cl b ) and renal (Cl r-24 ) clearances.
biotransformation and urinary excretion appear to be directly influenced by the number and type of halogen substituents on the C 2 carbon. Among the tri-HAs, substitution of bromine for chlorine increases both renal and nonrenal clearance (Table 2) . Conversely, all di-HAs are essentially eliminated by biotransformation as the Cl nr accounts for most of the Cl b and only (Table 2) . These quantitative and qualitative differences in clearance among the tested HAs result in an almost 14-fold range in blood elimination half-lives (Table 2) .
Closer inspection of the Cl r values suggests there is a marked difference between tri-and di-HAs in the degree of renal tubular secretion and reabsorption. Because only the unbound fraction of HA in plasma can undergo glomerular filtration, additional interpretation of renal clearance requires correction for plasma protein binding, which varied widely among the HAs. The values of Cl r corrected for plasma binding are shown in Table 6 . The unbound Cl r for the brominated tri-HAs approaches or exceeds the GFR for rats, which is 314 ml h Ϫ1 kg Ϫ1 (Davies and Morris, 1993) . This observation would indicate that renal clearance for the tri-HAs is largely determined by the extent of tubular secretion. This is especially apparent for TBA, whose unbound Cl r is more than threefold greater than the GFR and therefore must undergo considerable tubular secretion to account for such a large value (Janku, 1993) . In contrast, the Cl r for DCA, and to a lesser extent BCA and DBA, is well below the GFR and closer to the urine flow Bowden et al. (1998) . Values for BDCA, CDBA, and BCA were calculated using the Biobyte Co. data base (Dr. Ann Richard, personal communication).
b C Log P is the calculated Log p. Values for TCA, TBA, DCA, and DBA are from Richard and Hunter (1996) and are referenced to the un-ionized form of the haloacetate. Values for BDCA, CDBA, and BCA were calculated in a similar manner and were provided by Dr. Ann Richard (personal communication) .
c Log D is the distribution coefficient between n-octanol and buffer (pH 7.4 and 4.0). Mean Ϯ SD (n ϭ 3-5) is reported. Note. Values are mean Ϯ SD. Parameter estimates were calculated from the individual blood-concentration time profiles (n ϭ 4-6) using both compartmental and noncompartmental methods. The T max , C max , and K a for the tri-HAs were determined by the WinNonlin program. Model predicted values for T max and C max were not determined for the di-HAs (see Methods) and only the average of the observed values is reported for these HAs. The AUC 03ϱ and MRT were calculated using noncompartmental methods. Oral bioavailability was calculated from the ratio of the mean values for the AUC 03ϱ from the oral and iv doses. n.d., not determined.
a Values are not significantly different ( p Ͼ 0.08).
rate in rats which is reported to be 8.3 ml h Ϫ1 kg Ϫ1 (Davies and Morris, 1993) and is comparable to the average volume of urine collected over 24 h from rats used in this study (132 ml day Ϫ1 kg Ϫ1 ). Most notable among the di-HAs is DCA, where the unbound Cl r is clearly less than the urine flow rate ( Table  2 ). The best explanation for the close approximation of the unbound Cl r to urine flow rate is that DCA (and presumably BCA and DBA) undergo tubular reabsorption to an extent comparable to that of water (Rowland and Tozer, 1989) . These observations lead us to propose that urinary excretion of HAs is controlled by separate processes: tubular secretion for the tri-HAs and tubular reabsorption for the di-HAs.
It is now becoming established that di-HAs are almost exclusively eliminated via biotransformation in rodents. Previous in vitro studies have established that biotransformation of DCA primarily occurs in liver cytosol (Lipscomb et al., 1995) and is a glutathione-dependent process (James et al., 1997) mediated through a novel class of GST isoenzyme, GST-zeta (Tong et al., 1998a) . The initial metabolite of DCA has been identified as glyoxylic acid (Tong et al., 1998a) , which can then be further metabolized to glycolic acid or oxalic acid (Lin et al., 1993; Gonzalez-Leon et al., 1997) . The metabolism of the brominated di-HAs has not been thoroughly investigated, but limited in vitro data Tong et al., 1998b) combined with the results of the present study are consistent with the hypothesis that BCA and DBA are metabolized in a manner similar to DCA. However, both DBA and BCA appear to be more rapidly metabolized than DCA, which has a lower Cl nr . The more extensive metabolism of DBA and BCA is reflected in their comparatively low oral bioavailability (30 -47%), which is apparently due to greater first-pass metabolism (Table 3) .
Compared to the di-HAs, the tri-HAs undergo reduced metabolism and almost 30 times the quantity of parent HA can be recovered in the urine within 24 h of dosing (Table 2) . However, substantial metabolism of the brominated tri-HAs must still occur as the Cl nr accounts for the majority of the Cl b (Table  2) . Experimental studies on the metabolism of TCA and BDCA in mice also indicate that substitution of bromine for chlorine increases the metabolism of tri-HAs. In the B6C3F1 mouse, up to 60% of orally administered [
14 C]BDCA is excreted as CO 2 (Xu et al., 1995; Austin and Bull, 1997) compared to only 10% for [ 14 C]TCA (Larson and Bull, 1992; Xu et al., 1995) . Dichloroacetate has been shown to be a urinary metabolite of BDCA in mice after oral dosing (Xu et al., 1995) . The formation of DCA from BDCA was later shown to occur primarily in the microsomal fraction and was NADPH dependent in mouse liver (Austin and Bull, 1997) . These results would suggest that metabolism of HAs is compartmentalized within the hepatocyte, with the tri-HAs undergoing dehalogenation via a cytochrome P450-mediated process that generates the di-HA, which is subsequently acted upon by cytosolic GSTs and eventually accounts for the CO 2 production after tri-HA dosing. However, our results indicate that di-HA formation may not occur to the same extent in F344 rats as in mice. In the present study, no detectable blood or urine levels of a di-HA were observed after oral or iv tri-HA dosing. If the bulk of the Cl nr of the tri-HAs were due to initial dehalogenation and di-HA formation, then detectable levels of the corresponding di-HA would have been observed. Our inability to detect the di-HAs would indicate that metabolism of the tri-HAs in F344 rats proceeds through additional pathway(s) that do not generate a stable di-HA intermediate. Alternative metabolic pathways for the brominated tri-HAs have been proposed in mice, which include initial decarboxylation and formation of a halomethane (Xu et al., 1995; Austin and Bull, 1997) . Whether this pathway occurs in rats is unclear, and additional research is required to fully understand the complexity of tri-HA metabolism.
In contrast to the differences in elimination among HAs, there was remarkable similarity in the steady-state apparent volume of distribution (V ss ) and the first-order oral absorption rate (K a ) and MAT. The similarity in these parameters occurred despite large differences in plasma protein binding and physicochemical properties such as the ionization potential and C log P (Table 5 ). The size of the V ss for HAs approximated the total body water volume of rats (0.66 l/kg, Reinoso et al., 1997) , which indicates that HAs distribute uniformly outside the vascular system, and it is unlikely that any significant sequestering of HAs occurs in peripheral tissues. Because only the unbound fraction of HA in blood can diffuse into peripheral tissues, the similarity in V ss over a wide range of f u values implies that changes in blood and plasma binding among the HAs are matched to a similar degree in peripheral tissue binding (Toon and Rowland, 1983; Blakey et al., 1997) . This would be another indication that HA binding to macromolecules is nonspecific in character. These conclusions may be useful in the prediction of the tissue dosimetry of HAs. There has been interest in the development of physiologically based pharmacokinetic models (PBPK) that describe the tissue distribution of HAs in rats (Fisher et al., 1991; Clewell et al., 1995; Stenner et al., 1998 ). An important parameter of PBPK models is the tissue/blood partition coefficient. Our pharmacokinetic analysis suggests that tissue/blood partition coefficients should approximate 1 and would be similar for all the HAs used in this study. The absence of any clear trend in the K a or MAT among the brominated HAs is at first surprising considering the range of C log P values (Table 5 ). The C log P values represent the lipophilicity of the fully unionized forms of the HAs, which would not occur at physiological pHs given their low pK a values (Table 5) . A better predictor of lipophilicity for the HAs at physiological pH ranges is the distribution coefficients (log D 4-7.4 ) shown in Table 5 . These experimentally measured log D 4-7.4 values for the HAs varied much less than the C log P values. Assuming that the absorption of HAs is primarily due to passive diffusion, the similarity in absorption among the HAs would suggest that little variation in membrane permeability exists at gastrointestinal pH values. Interestingly, the MATs for the fully chlorinated HAs, TCA, and DCA were much longer than those for the brominated HAs. Perhaps most difficult to explain is the multiple blood peaks observed after oral dosing with the di-HAs, especially DCA (Fig. 5C, D) . This result is in contrast to previous oral dosing studies of DCA in rats, which did not report multiple peaks in the concentrationtime profiles (Evans, 1982; Larson and Bull, 1992) . However, in the previous studies, only a few (3-5) samples were collected, and it is likely that the occurrence of multiple peaks was missed. An obvious explanation for the multiple peaking would be enterohepatic recirculation because the secondary blood maxima occur during a time period associated with bile secretion and reabsorption. However, enterohepatic recycling does not appear to explain this phenomenon, as only small quantities of DCA were excreted into the bile and bile removal did not eliminate the multiple peaks (Fig. 5D) . A more likely explanation is discontinuous absorption from the stomach and intestinal tract. This mechanism has been proposed to explain multiple peaking observed with other xenobiotics, including halomethanes, which do not undergo significant enterohepatic recycling (Suttle et al., 1992; Langguth et al., 1994; Lilly et al., 1998) . However, it remains unclear why the di-HAs would exhibit discontinuous absorption when the tri-HAs apparently do not.
An additional aspect of di-HA toxicokinetics that is difficult to explain was the tailing or flattening of the blood concentration-time profiles after iv injection. This phenomenon was most visible for BCA; however, similar observations have been made for DCA in clinical pharmacokinetic studies after iv dosing. In clinical studies, high intersubject and interstudy variation in elimination half-life of DCA is common Fox et al., 1996) . This variation has caused disagreement in the interpretation of blood or plasma profiles when clearance-volume compartmental modeling approaches are employed to analyze the data, as it is uncertain whether a one-, two-, or three-compartment model is most appropriate . This has led to confusion regarding estimates of the apparent volume of distribution and total clearance for DCA, due to the variety of models that have been applied (see Henderson et al., 1997; Fox et al., 1996; Shangraw and Fisher, 1996 for three different modeling approaches).
The statistical moment analysis applied in this study avoids many of these problems because calculation of the AUC 03ϱ was largely unaffected by the use of a truncated or complete concentration-time profile in the data analysis ( Table 2 ). The primary differences in the kinetic parameters were the estimates of terminal half-life, which appeared to increase up to fivefold (e.g., BCA) when data collected beyond 4 h were included in the analysis. Recently, it has been demonstrated that DCA autoinhibits its metabolism (Gonzalez-Leon et al., 1997; James et al., 1997) , which leads to a substantial reduction in its elimination in rats (Gonzalez-Leon et al., 1997) . We have also obtained preliminary evidence that DBA and BCA autoinhibit their metabolism as well (Gonzalez-Leon et al., 1999) . Thus, it is tempting to speculate that the apparent delay in the excretion of the residual portion of the dose (Ͼ4-h dosing) is due to a reduction in liver metabolism resulting from enzyme inactivation during the experiment. However, this hypothesis seems unlikely, given that the principal effects of enzyme inactivation during pharmacokinetic studies occur immediately after dosing and would not be expected to cause a change in the terminal half-life (Gray and Tam, 1991) .
CONCLUSION
In conclusion, drinking water typically contains a mixture of HAs whose constituents may vary regionally, seasonally, and according to the type of disinfection method used (Richardson et al., 1996; Williams et al., 1997; Chen and Weisel, 1998) . This presents a challenge for risk assessments of these compounds, and simplifying assumptions regarding their disposition and toxicity will need to be made. Our toxicokinetic studies indicate that the disposition of HAs can be broadly grouped into three categories according to the extent of biotransformation and urinary excretion. Trichloroacetate is the most biologically persistent HA exhibiting low metabolism and moderate urinary excretion. The di-HAs are highly metabolized and undergo low urinary excretion. The brominated triHAs are intermediate in character between TCA and the diHAs, exhibiting both high metabolism and urinary excretion. Future efforts at developing predictive models for HA toxicokinetics should focus on the role of halogen substitution in determining metabolism and urinary excretion of the HAs.
